- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04394858
Prueba de la adición de un medicamento contra el cáncer, olaparib, a la quimioterapia habitual (temozolomida) para el cáncer neuroendocrino avanzado
Un ensayo de fase II prospectivo y multiinstitucional que evalúa temozolomida frente a temozolomida y olaparib para feocromocitoma y paraganglioma avanzados
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.
Descripción general del estudio
Estado
Condiciones
- Feocromocitoma metastásico de la glándula suprarrenal
- Paraganglioma metastásico
- Feocromocitoma irresecable de la glándula suprarrenal
- Paraganglioma irresecable
- Feocromocitoma avanzado de la glándula suprarrenal
- Paraganglioma avanzado
- Feocromocitoma y paraganglioma simpático de las glándulas suprarrenales en estadio III AJCC v8
- Feocromocitoma y paraganglioma simpático de las glándulas suprarrenales en estadio IV AJCC v8
Descripción detallada
PRIMARY OBJECTIVE:
I. To compare the progression-free survival (PFS) of patients with advanced pheochromocytoma and paraganglioma (APP) receiving temozolomide (dose dense) and olaparib to that of patients receiving temozolomide (pulse dose) alone.
SECONDARY OBJECTIVES:
I. To compare the overall survival (OS) of patients with APP receiving temozolomide (dose dense) and olaparib versus (vs.) temozolomide (pulse dose) alone.
II. To compare the objective response rate (ORR) associated with temozolomide (dose dense) and olaparib vs. temozolomide (pulse dose) alone in patients with APP.
III. To evaluate and compare the toxicity profile of temozolomide-based combinations (temozolomide [dose dense] and olaparib vs. temozolomide [pulse dose]) in patients with APP using Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO)-CTCAE.
OTHER OBJECTIVE:
I. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
EXPLORATORY OBJECTIVES:
I. To assess biochemical response: serum catecholamines and metanephrines; urine catecholamines and metanephrines.
II. To assess biomolecular markers associated with clinical outcome: germline succinyl dehydrogenase (SDH) mutations and tumor status of the repair enzyme methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive temozolomide orally (PO) once daily (QD) and olaparib PO twice daily (BID) on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with contrast or magnetic resonance imaging (MRI) throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
ARM II: Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
Patients discontinuing treatment due to reasons other than disease progression are followed every 12 weeks until disease progression, then every 6 months until 5 years after registration. Patients discontinuing treatment due to disease progression are followed every 6 months for 5 years after registration.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Estados Unidos, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Estados Unidos, 99504
- Anchorage Radiation Therapy Center
-
-
California
-
Burbank, California, Estados Unidos, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Holy Cross Hospital
-
Gainesville, Florida, Estados Unidos, 32610
- UF Health Cancer Institute - Gainesville
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Comprehensive Cancer Center
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Estados Unidos, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Estados Unidos, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
Orland Park, Illinois, Estados Unidos, 60462
- University of Chicago Medicine-Orland Park
-
Ottawa, Illinois, Estados Unidos, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare-Princeton
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Washington, Illinois, Estados Unidos, 61571
- Illinois CancerCare - Washington
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institutes of Health Clinical Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana-Farber Cancer Institute
-
Newton, Massachusetts, Estados Unidos, 02467
- Dana-Farber Cancer Institute - Chestnut Hill
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Estados Unidos, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Estados Unidos, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Estados Unidos, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Estados Unidos, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Estados Unidos, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Estados Unidos, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Estados Unidos, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, Estados Unidos, 48503
- Hurley Medical Center
-
Flint, Michigan, Estados Unidos, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Estados Unidos, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Estados Unidos, 48503
- Cancer Hematology Centers - Flint
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Lansing, Michigan, Estados Unidos, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Estados Unidos, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Estados Unidos, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Estados Unidos, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Estados Unidos, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Estados Unidos, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Pontiac, Michigan, Estados Unidos, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Rochester Hills, Michigan, Estados Unidos, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Estados Unidos, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Estados Unidos, 48601
- MyMichigan Medical Center Saginaw
-
Sterling Heights, Michigan, Estados Unidos, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Estados Unidos, 48764
- MyMichigan Medical Center Tawas
-
Warren, Michigan, Estados Unidos, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Estados Unidos, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Estados Unidos, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Estados Unidos, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Burnsville, Minnesota, Estados Unidos, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Estados Unidos, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Estados Unidos, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Mercy Hospital
-
Edina, Minnesota, Estados Unidos, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Estados Unidos, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Estados Unidos, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Estados Unidos, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Estados Unidos, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55454
- Health Partners Inc
-
Monticello, Minnesota, Estados Unidos, 55362
- Monticello Cancer Center
-
New Ulm, Minnesota, Estados Unidos, 56073
- New Ulm Medical Center
-
Princeton, Minnesota, Estados Unidos, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Estados Unidos, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Estados Unidos, 55102
- United Hospital
-
Shakopee, Minnesota, Estados Unidos, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Estados Unidos, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Estados Unidos, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Estados Unidos, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Estados Unidos, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Estados Unidos, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
-
Montana
-
Missoula, Montana, Estados Unidos, 59802
- Saint Patrick Hospital - Community Hospital
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Estados Unidos, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Estados Unidos, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Albany Medical Center
-
Commack, New York, Estados Unidos, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Estados Unidos, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Estados Unidos, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Estados Unidos, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Estados Unidos, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Estados Unidos, 97420
- Bay Area Hospital
-
Newberg, Oregon, Estados Unidos, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Estados Unidos, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Estados Unidos, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Lehigh Valley Hospital - Muhlenberg
-
East Stroudsburg, Pennsylvania, Estados Unidos, 18301
- Pocono Medical Center
-
Hazleton, Pennsylvania, Estados Unidos, 18201
- Lehigh Valley Hospital-Hazleton
-
-
Texas
-
Austin, Texas, Estados Unidos, 78723
- Dell Children's Medical Center of Central Texas
-
-
Utah
-
Farmington, Utah, Estados Unidos, 84025
- Farmington Health Center
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- University of Utah Sugarhouse Health Center
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- University of Virginia Cancer Center
-
-
Washington
-
Aberdeen, Washington, Estados Unidos, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellingham, Washington, Estados Unidos, 98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia, Washington, Estados Unidos, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Estados Unidos, 98026
- Swedish Cancer Institute-Edmonds
-
Everett, Washington, Estados Unidos, 98201
- Providence Regional Cancer Partnership
-
Issaquah, Washington, Estados Unidos, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Estados Unidos, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Estados Unidos, 98503
- Providence Regional Cancer System-Lacey
-
Longview, Washington, Estados Unidos, 98632
- PeaceHealth Saint John Medical Center
-
Seattle, Washington, Estados Unidos, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Estados Unidos, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Estados Unidos, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Estados Unidos, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Estados Unidos, 98584
- Providence Regional Cancer System-Shelton
-
Vancouver, Washington, Estados Unidos, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Estados Unidos, 99362
- Providence Saint Mary Regional Cancer Center
-
Yelm, Washington, Estados Unidos, 98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
New Richmond, Wisconsin, Estados Unidos, 54017
- Cancer Center of Western Wisconsin
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Documentation of disease
- Histologic documentation: Histologically-proven advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma
- Stage: Advanced (metastatic or unresectable primary) disease
- Tumor site: Histologically-proven pheochromocytoma or paraganglioma
- Radiographic evaluation: Radiographic evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 in the 12 months prior to registration
-
Measurable disease
- Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as >= 1 cm with CT or MRI (or >= 1.5 cm for lymph nodes). Non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
-
Prior treatment with other somatostatin analog, chemotherapy, radiotherapy (including peptide radionuclide receptor therapy [PRRT]), or surgery must be completed >= 28 days prior to registration. Patients must have recovered from any effects of any major surgery prior to registration
-
Prior treatment with radiolabeled metaiodobenzylguanidine (MIBG) must be completed >= 12 weeks prior to registration and lifetime cumulative 131I-MIBG dose must be < 1000 MBq kg^-1 (36 mCi kg^-1)
-
Prior treatment with antibiotics must be completed >= 7 days prior to registration
-
No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor
-
No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
-
Contraception
- Therapy utilized in this trial is associated with medium/high fetal risk
- Women of childbearing potential and their partners, who are sexually active, must agree to use two highly effective forms of contraception in combination. This should be started from the time of registration and continue throughout the period of taking study treatment and for at least 1 month after last dose of study drug(s), or they must totally/truly abstain from any form of sexual intercourse
- Male patients must use a condom during treatment and for 3 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential. Male patients should not donate sperm throughout the period of taking study drug(s) and for 3 months following the last dose of study drug(s)
-
Age >= 12 years
-
Eastern Cooperative Oncology Group (ECOG) Patients ≥ 18 years of age: Performance status: 0-2
- Patients < 16 years of age: Lansky ≥ 50%
- Patients 16 to < 18 years of age: Karnofsky ≥ 50%
- Patients ≥ 18 years of age: ECOG performance status ≤ 2
-
Absolute neutrophil count >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Hemoglobin >= 10 mg/dL if prior radionuclide therapy Hemoglobin >= 8 mg/dL if no prior radionuclide therapy
- In the absence of transfusion within the previous 24 hours. Radionuclide therapy includes PRRT or MIBG
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Except in the case of Gilbert's syndrome, then total bilirubin must be =< 3.0 x ULN
-
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
-
Creatinine < 1.5 x ULN OR calculated (calc.) creatinine clearance > 50 mL/min
-
Calculated by Cockcroft-Gault equation
-
By Cockcroft-Gault equation. Alternatively, for patients < 18 years of age, maximum serum creatinine ≤ the below age-sex-specific norms:
- Age 12 years: Male 1.2; female 1.2
- Age 13 to < 16 years: Male 1.5; female 1.4
- Age 16 to < 18 years: Male 1.7; female 1.4
-
-
No indication of uncontrolled, potentially reversible cardiac condition(s) as determined by investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's formula-corrected QT interval [QTcF] prolongation > 500 msec, electrolyte disturbances, etc.) and no known congenital long QT syndrome
-
No extensive bilateral lung disease or pneumonitis
-
No abnormal organ or bone marrow function =< 28 days prior to registration
-
Patients with human immunodeficiency virus (HIV) positivity are allowed if CD4 count > 250 cells/uL and they have an undetectable HIV viral load within 6 months of registration
-
No active infection
-
No history of myelodysplastic syndrome (MDS) (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
-
No known gastrointestinal condition(s) that might predispose for drug intolerability or poor drug absorption
-
No known medical condition causing an inability to swallow oral formulations of agents
-
No history of allergic reaction attributed to compounds of similar chemical or biologic composition to PARP inhibitors
-
Concurrent use of combination antiretroviral therapy (ART) is not permitted
-
Chronic concomitant treatment with strong or moderate CYP3A4 inducers or inhibitors is not allowed. Patients must discontinue the agent(s) >= 21 days prior to registration; enzalutamide and/or phenobarbital must be discontinued >= 5 weeks prior to registration
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm I (temozolomide, olaparib)
Patients receive temozolomide PO QD and olaparib PO BID on days 1-7. Treatment with temozolomide repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Cycles of olaparib repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. |
Ancillary studies
Otros nombres:
Undergo MRI
Otros nombres:
Given PO
Otros nombres:
Undergo collection of blood samples
Otros nombres:
Given PO
Otros nombres:
Undergo CT with contrast
Otros nombres:
|
|
Comparador activo: Arm II (temozolomide)
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression. |
Ancillary studies
Otros nombres:
Undergo MRI
Otros nombres:
Given PO
Otros nombres:
Undergo collection of blood samples
Otros nombres:
Undergo CT with contrast
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS)
Periodo de tiempo: From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
|
Will be compared between treatment arms using the un-stratified log-rank test at one-sided level of 0.11 and the p-value will be used for decision making. The hazard ratio will be estimated using a Cox proportional hazards model and the 95% confidence interval for the hazard ratio will be provided. Results from a stratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer-Crowley methodology will be used to construct the 95% confidence interval for the median PFS for each treatment arm. |
From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall survival (OS)
Periodo de tiempo: From randomization to death due to any cause, assessed up to 5 years
|
Patients who are alive will be censored at last follow-up. The distribution of survival time will be estimated using the method of Kaplan-Meier. OS will be compared between treatment arms using the log-rank test. OS medians, survival rates and hazard ratio will be estimated along with 95% confidence intervals. |
From randomization to death due to any cause, assessed up to 5 years
|
|
Objective response
Periodo de tiempo: Up to 5 years
|
Will be assessed by RECIST version 1.1 criteria. Will be estimated using objective response rate where objective response rate is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST version 1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% binomial confidence intervals. |
Up to 5 years
|
|
Incidence of adverse events
Periodo de tiempo: Up to 5 years
|
Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The term toxicity is defined as adverse events that are classified as possibly, probably, or definitely related to study treatment. Toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events standard toxicity grading. Similarly, scores (0-4) and the maximum score for each Patient-Reported Outcomes-CTCAE item will be recorded for each patient. |
Up to 5 years
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Biochemical response
Periodo de tiempo: Up to 5 years
|
Levels of chromogranin A, urine and/or plasma catecholamines and metanephrines may predict response to therapy. The proportion of patients with a biochemical response of partial response or better, as determined by plasma and/or urine catecholamines and metanephrines, will be calculated, and a 95% confidence interval will be placed on this proportion. For each factor, we will calculate the mean +/- standard deviation, minimum, maximum, and quartiles; in addition, we will generate box and whisker plot. |
Up to 5 years
|
|
Biomolecular markers associated with clinical outcome
Periodo de tiempo: Up to 5 years
|
Will analyze for methyltransferase (MGMT) methylation expression in archival tumors and correlate with the radiographic response rate in metastatic pheochromocytoma/paraganglioma. This is hypothesis generated box and whisker plot. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jaydira Del Rivero, Alliance for Clinical Trials in Oncology
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Feocromocitoma
- Paraganglioma
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Azoles
- Acciones farmacológicas
- Acciones y usos químicos
- Dacarbazina
- Triazenes
- Imidazoles
- Usos especializados de productos químicos
- Técnicas de química, analítica
- Análisis de espectro
- Usos diagnósticos de productos químicos
- Temozolomida
- Manejo de muestras
- Espectroscopía de resonancia magnética
- olaparib
- Medios de contraste
Otros números de identificación del estudio
- NCI-2020-03379
- U10CA180821 (Subvención/contrato del NIH de EE. UU.)
- NCI-2020-03379 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- A021804 (Otro identificador: CTEP)
- A021804 (Otro identificador: Alliance for Clinical Trials in Oncology)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .